Trials / Completed
CompletedNCT02809443
GLS-5700 in Dengue Virus-Naïve Adults
Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- GeneOne Life Science, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus. ZIKA-001 is the first in man clinical trial of this vaccine which encodes for the premembrane-membrane and envelope regions of Zika virus.
Detailed description
GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GLS-5700 | GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2017-11-01
- Completion
- 2017-12-01
- First posted
- 2016-06-22
- Last updated
- 2024-12-24
- Results posted
- 2024-12-24
Locations
3 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02809443. Inclusion in this directory is not an endorsement.